Reason for request
Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals in the ‘Central neuropathic pain in adults’ indication extension.
Clinical Benefit
| Substantial |
The actual benefit of LYRICA in the treatment of central neuropathic pain in adults is substantial. |
Clinical Added Value
| no clinical added value |
Lyrica does not provide any improvement in actual benefit (IAB level V) over the usual management of central neuropathic pain in adults. |
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
TwUfgxJ380hF6cxa
